Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease

Background: We evaluated the erythropoietic effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in type 2 diabetes patients with anemia of chronic kidney disease. Methods: Nine diabetes patients were enrolled and administered 100 mg canagliflozin once a day for 12 weeks. The patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruyama, Takashi, Takashima, Hiroyuki, Oguma, Hidetaka, Nakamura, Yoshihiro, Ohno, Michiko, Utsunomiya, Kei, Furukawa, Tetsuya, Tei, Ritsukou, Abe, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875696/
https://www.ncbi.nlm.nih.gov/pubmed/31385724
http://dx.doi.org/10.1089/dia.2019.0212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875696/
https://www.ncbi.nlm.nih.gov/pubmed/31385724
http://dx.doi.org/10.1089/dia.2019.0212

Ejemplares similares